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Abstract Acute dystonia is an abrupt event mainly related
to toxicity of drugs such as antiemetics, antipsychotics,
anti-acids, and, more rarely, tricyclic antidepressants. Use
of amitriptyline in metachromatic leukodystrophy (MLD), a
lysosomal storage disorder (LSD) due to arylsulfatase A
deficiency, is suggested to control neurological pain and
irritability. We describe a patient with MLD who experi-
enced acute dystonia as a side effect of low dosage of
amitriptyline. The distribution of psychotropic drugs,
including antidepressants, depends upon lysosomal
trapping which is inefficient in LSD. The defective
lysosomal depot might raise cerebral levels of amitriptyline,
thus enhancing its adverse effects.
Physicians caring for children with MLD treated with
psychotropic drugs should be aware of such adverse events
which are potentially related to lysosomal dysfunction. This
experience raises a potential concern about the appropriate
dose of amitriptyline in patients with MLD.
Introduction
Drug-induced dystonic reactions are the most common causes
of acquired dystonia in childhood (van Harten et al. 1999).
Side effects profile of amitriptyline includes sedation, dry
mouth, impaired cardiovascular and central nervous system
(CNS) function (Gore et al. 2006); among extrapyramidal
manifestations, acute dystonia has been reported in cases of
long-term or overdose of amitriptyline treatment (Ornadel
et al. 1999; Finder et al. 1982; Lee 1988). In the literature,
two cases of pediatric amitriptyline poisoning are described
(Baysal et al. 2007; Doherty et al. 2012).
Metachromatic leukodystrophy (MLD) is an autosomal
recessive lysosomal storage disorder (LSD) due to arylsul-
fatase A (ARSA) enzyme deficiency, resulting in rapid and
progressive neurologic and cognitive deterioration. Irrita-
bility and neurologic pain are significant problems for the
management of patients in advanced stages of the disease
and evidence-based treatment options for these issues are
lacking. Practical hints can be found in the document by the
Evanosky Foundation (The Evanosky Foundation 2008).
Listing of the suggested medications include: myorelaxant
agents (Dantrium, Baclofen), anti-reflux, anti-seizure, and
anti-inflammatory medications. Amitriptyline is suggested
to control irritability and pain.
We report a 3.7-year-old girl affected by MLD who
presented with an acute episode of dystonia related to
amitriptyline which was given to control irritability and pain.
Case Report
A 3.7-year-old girl affected by the late infantile form of
MLD, confirmed by both biochemical and molecular
analyses, is regularly followed at the Department of
Pediatrics of Federico II, University of Naples, Italy.
Progressive spasticity had led to permanent plantar flexion
of the feet at rest, despite baclofen treatment at the
dosage of 2 mg/kg/day. Moreover, the girl began to
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suffer from bouts of crying lasting for several hours during
the night.
We used a modified Ashworth scale (Lee et al. 1989) to
rate her severity of hypertonia: on the right side, passive
movement was difficult and scored 3, on the left, range of
motion and spasticity matched to a score of 4. After an
extensive workup carried out in order to exclude treatable
causes of pain, including gallbladder stone (Kim et al.
1996) dantrolene sodium (6 mg/kg/day) was added to
therapy, and resulted in some improvements on the Ash-
worth scale: spasticity improved within 2 days to a score of
3 bilaterally.
Treatment with amitriptyline was started to improve
crying and neurological pain, as suggested by the Evanosky
paper (The Evanosky Foundation 2008). The starting dose
was 0.2 mg/kg daily orally for the first 2 days, gradually
raised to 0.4 mg/kg daily in the third and the fourth day,
lower doses than those recommended for pediatric age
(Fournier-Charrière 2010).
After 4 days of treatment, muscular tone further
improved (bilaterally score 2 according to Ashworth scale).
However, on the morning of the fifth day of amitryptiline
treatment, the patient experienced generalized malaise,
vomiting, profuse sweating, tachycardia (heart rate 190/
min), tachypnea (respiration rate about 28/min), and
mydriasis. A few hours later, she abruptly developed
worsening of hypertonia with severe generalized muscle
contractions and opisthotonos (score 4 bilaterally, according
to the Ashworth scale). Furthermore, a forced head and
gaze deviation to the right with horizontal nystagmus
ensued, followed by trismus, and buccolingual automatisms
(Fig. 1). Oxygen saturation was in the normal range (about
99–100%). The patient appeared unresponsive to her
surroundings with an ill-defined state of consciousness.
The video/EEG monitoring showed high amplitude, back-
ground activity of 3 to 4 Hz, with an excess of muscular
artifacts. In view of the absence of epileptic abnormalities, a
diagnosis of acute generalized dystonia was entertained and
treatment with 0.16 mg/kg of diazepam intravenously was
started.
As an amitriptyline-induced dystonic reaction could be
reasonably foreseen, the drug was immediately discontin-
ued. Common antidotes as anticholinergic benztropine were
not used because of the tachycardia.
The patient showed a gradual reversion of the opistho-
tonos and resolution of all autonomic symptoms and signs.
Video/EEG recording was repeated after 1 week from the
acute episode and did not show any epileptic abnormalities.
The Naranjo scale (Naranjo et al. 1981) indicated that
the adverse event was probably caused by amitriptyline
(causality algorithm yielded a score of 7).
The chronic unexplained irritability in the little child has
been treated subsequently with Gabapentin, 5 mg/kg per
dose as previously described (Hauer et al. 2007), achieving
successful results in decreasing irritability and crying,
bettering nocturnal sleep.
Discussion
Drugs inducing extrapyramidal symptoms include anticon-
vulsants (Van Harten et al. 1999), antiemetic and anti-
nausea drugs (Patel et al. 2011), atypical and typical
antipsychotics, tricyclic antidepressants (TCAs) (Arnone
et al. 2002), triptans (Garcia et al. 1994), antitussive drugs
(Polizzi et al. 2001), histamine H2-receptor antagonists
(Kapur et al. 1999), and antihistamine agents (Esen et al.
2008). Misdiagnosis is common, and video/EEG monitor-
ing is useful to rule out epileptic fits.
Amitryptyline, a TCA, has pronounced side effects that
tend to be most acute in the elderly because they frequently
require multiple medications that increase the potential
Fig. 1 Girl affected with MLD presenting with an acute dystonia following amitriptyline treatment. Note the opisthotonos with forced head and
gaze deviation to the right, grimacing, and trismus
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drug-drug interactions (Gore et al. 2006). Tremor, dysar-
thria, and akathisia due to amitriptyline have been
observed. Only few cases of acute dystonia due to
amitriptyline have been reported in adults, ascribed to
overdose and/or long-term therapy, drug interactions
(Ornadel et al. 1999; Finder et al. 1982; Lee 1988).
List of medications potentially interacting with amitrip-
tyline includes baclofen (Gore et al. 2006). In our young
patient, concurrent administration of baclofen with the
amitriptyline may have lowered the threshold for this
unwanted adverse effect.
Among pediatric patients, acute neurological mani-
festations, like tonic-clonic seizures, due to amitriptyline
overdose (47 mg/kg and 14 mg/kg respectively) have been
described sporadically (Baysal et al. 2007; Doherty et al.
2012). In children, doses of 5 mg/kg are potentially toxic
while severe toxicity is encountered at 20 mg/kg dose
(Vernon and Gleich 1997). In the case herein reported, the
patient presents with acute dystonia at dosage of amitripty-
line within 0.2–0.4 mg/kg daily.
The causal relationship between acute dystonia and
amitriptyline in our patient is based on (1) close temporal
correlation between drug administration and onset of the
dystonia, (2) improvement following drug withdrawal, (3)
no recurrence of symptoms after the drug was discontinued,
and (4) exclusion of other possible causes. In addition,
according to the Naranjo adverse drug reaction probability
scale, the event is assigned as probable (Lee et al. 1989).
Dystonia has been rarely described as a feature of MLD
(Baumann et al. 2002). This may suggest a particular
predisposition for dystonia episodes in MLD patients
following centrally acting drugs.
A possible pathomechanism underlying this unexpected
toxic effect of low-dose amitriptyline may depend upon
lysosomal dysfunction of MLD. Tissue distribution of
psychotropic drugs depends on phospholipid binding and
lysosomal trapping, which play an important role, parti-
cularly for drug biodistribution within the central nervous
system (CNS) (Daniel et al. 2001). A decrease in the
concentration of psychotropic drugs in lysosomes, as a result
of lysosomal dysfunction in LSDs, may result in altered
intracellular distribution and/or drug uptake in neuronal and
glial cells, which ultimately might lead to enhancement of
the drug biological effect (Daniel 2003). Therefore, we
speculate that impaired lysosomal trapping of amitriptyline
in the patient reported might lead to increased drug CNS
levels, which resulted in drug intoxication. This mechanism
of drug toxicity could be responsible for the onset of
extrapyramidal signs also in other previously reported
patients with other LSDs, receiving psychotropic drugs.
In their review of 20 patients with mucopolysacchar-
idosis type III, treated with neuroleptic drugs (lamotrigine,
risperidone, and olanzapine), Tchan and Sillence (2009)
reported five patients with a clear relationship between drug
assumption and extrapyramidal symptoms (included acute
dystonia). Moreover, Shapiro et al. (2006) reviewed 44
adults with late-onset Tay-Sachs disease who experienced
worsening of neurologic symptoms (weakness, incoordina-
tion, imbalance, tremor, dysarthria, cognitive decline, and
dystonia) following treatments with medications such as
haloperidol, risperidone, and chlorpromazine.
The above-mentioned psychotropic drugs have been
proved to share lysosomotropic properties (Daniel et al.
2001). We suggest that adverse extrapyramidal manifesta-
tions reported in patients with LSDs taking psychotropic
drugs could be related to defective lysosomal drugs uptake
and disposal.
In summary, we report a patient with MLD who
developed acute dystonia following amitriptyline therapy.
Patients with a defective lysosomal depot might be
prone to drug toxicity even at doses falling within or
lower the recommended dose range. Treatment of irrit-
ability and neurological pain in patients with MLD is
often difficult, since it may require the use of multiple
medications (increasing potential drug-drug interactions),
appropriate dosage, and monitoring for undesirable medical
consequences.
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